Pages that link to "Q33935430"

The following pages link to Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children (Q33935430):

Displaying 24 items.

• Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis (Q26849714) (← links)
• Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants (Q28473083) (← links)
• Adaptive Landscape by Environment Interactions Dictate Evolutionary Dynamics in Models of Drug Resistance (Q28552806) (← links)
• Spatiotemporal mathematical modelling of mutations of the dhps gene in African Plasmodium falciparum (Q30541962) (← links)
• Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana (Q33336570) (← links)
• Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: A randomized, placebo controlled trial (Q33394777) (← links)
• Malaria in infants below six months of age: retrospective surveillance of hospital admission records in Blantyre, Malawi (Q33587448) (← links)
• Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy (Q34737758) (← links)
• The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women (Q35965229) (← links)
• A pivot mutation impedes reverse evolution across an adaptive landscape for drug resistance in Plasmodium vivax (Q36503457) (← links)
• Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen (Q36536401) (← links)
• Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present. (Q37390583) (← links)
• Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women (Q37392749) (← links)
• Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis (Q37607325) (← links)
• Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges (Q37738205) (← links)
• Intermittent preventive treatment against malaria: an update (Q37747411) (← links)
• Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children (Q38071558) (← links)
• Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. (Q38901047) (← links)
• Malaria treatment using novel nano-based drug delivery systems (Q39122575) (← links)
• Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy (Q43272249) (← links)
• Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations. (Q46405195) (← links)
• Assessment of Clinical Pharmacokinetic Drug-Drug Interaction of Antimalarial Drugs α/β-Arteether and Sulfadoxine-Pyrimethamine (Q47998942) (← links)
• Population Pharmacokinetic properties of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria (Q49791979) (← links)
• Exposure to ambient air causes degradation and decreased in vitro potency of buparvaquone and parvaquone (Q99240213) (← links)